/Biogen%20Inc%20logo%20on%20laptop-by%20monticello%20via%20Shutterstock.jpg)
Valued at a market cap of $18.9 billion, Biogen Inc. (BIIB) is a biotechnology company that discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The Cambridge, Massachusetts-based company is scheduled to announce its fiscal Q2 earnings for 2025 before the market opens on Thursday, Jul. 31.
Before this event, analysts project this biotech company to report a profit of $4.03 per share, down 23.7% from $5.28 per share in the year-ago quarter. The company has surpassed Wall Street’s bottom-line estimates in three of the last four quarters, while missing on another occasion. Its earnings of $3.02 per share in the previous quarter fell short of the consensus estimates by 7.4%.
For the full year, analysts expect Biogen to report EPS of $14.84, down 9.9% from $16.47 in fiscal 2024. Nonetheless, its EPS is expected to grow by 2.6% year-over-year to $15.23 in fiscal 2026.
Shares of BIIB have declined 43.6% over the past 52 weeks, considerably underperforming both the S&P 500 Index's ($SPX) 12.7% uptick and the Health Care Select Sector SPDR Fund’s (XLV) 11.8% drop over the same time frame.
Biogen released its Q1 results on May 1, and its shares rose 2.2% in the following trading session. Its revenue improved 6.2% year-over-year to $2.4 billion, primarily driven by progress in its commercial portfolio transformation, with growth from launch products in Alzheimer's disease, rare disease, and postpartum depression more than doubling year-over-year. However, despite the revenue growth, its adjusted EPS declined 17.7% from the year-ago quarter to $3.02.
Wall Street analysts are moderately optimistic about Biogen’s stock, with an overall "Moderate Buy" rating. Among 33 analysts covering the stock, 14 recommend "Strong Buy," one indicates a "Moderate Buy," and 18 suggest "Hold.” The mean price target for BIIB is $171.41, implying a 33.2% premium from the current levels.
On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
